Drugs / IM92 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05275062 | Feb 2022 → Mar 2024 | gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma | Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IM92 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05275062 ↗ |
| Modality | Cell therapy | “IM92 CAR-T cells” NCT05275062 ↗ |